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Abnormality in glutamine–glutamate cycle in the cerebrospinal
ﬂuid of cognitively intact elderly individuals with major
depressive disorder: a 3-year follow-up study
K Hashimoto1, D Bruno2, J Nierenberg3,4, CR Marmar4, H Zetterberg5,6, K Blennow5 and N Pomara3,4
Major depressive disorder (MDD), common in the elderly, is a risk factor for dementia. Abnormalities in glutamatergic
neurotransmission via the N-methyl-D-aspartate receptor (NMDA-R) have a key role in the pathophysiology of depression. This study
examined whether depression was associated with cerebrospinal ﬂuid (CSF) levels of NMDA-R neurotransmission-associated amino
acids in cognitively intact elderly individuals with MDD and age- and gender-matched healthy controls. CSF was obtained from 47
volunteers (MDD group, N=28; age- and gender-matched comparison group, N=19) at baseline and 3-year follow-up (MDD group,
N=19; comparison group, N=17). CSF levels of glutamine, glutamate, glycine, L-serine and D-serine were measured by high-
performance liquid chromatography. CSF levels of amino acids did not differ across MDD and comparison groups. However, the
ratio of glutamine to glutamate was signiﬁcantly higher at baseline in subjects with MDD than in controls. The ratio decreased in
individuals with MDD over the 3-year follow-up, and this decrease correlated with a decrease in the severity of depression. No
correlations between absolute amino-acid levels and clinical variables were observed, nor were correlations between amino acids
and other biomarkers (for example, amyloid-β42, amyloid-β40, and total and phosphorylated tau protein) detected. These results
suggest that abnormalities in the glutamine–glutamate cycle in the communication between glia and neurons may have a role in
the pathophysiology of depression in the elderly. Furthermore, the glutamine/glutamate ratio in CSF may be a state biomarker for
depression.
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INTRODUCTION
Late-life depression, one of the most common psychiatric
disorders in older adults, is associated with signiﬁcant functional
impairment, variable treatment response, high recurrence rates,
chronicity and high rates of medical comorbidity and mortality.1,2
Multiple lines of evidence suggest that late-life depression is a risk
factor for the development of dementia, including Alzheimer’s
disease (AD) and vascular dementia.2–4 However, the precise
molecular mechanisms underlying the relationship between late-
life depression and dementia risk remain unknown. Better
understanding this relationship would likely contribute to
improving preventive interventions in the elderly.
Glutamate (or L-glutamic acid) has an important role as the
major excitatory neurotransmitter in the central nervous system.
In the brain, glutamate is synthesized from glutamine by
glutaminase, and metabolized to glutamine by glutamine
synthetase (GS) in astrocytes.5–8 Accumulating evidence suggests
that abnormalities in the glutamatergic neurotransmission via the
N-methyl-D-aspartate receptor (NMDA-R) have a key role in the
pathophysiology of major depressive disorder (MDD).5,6,8–12
Hashimoto et al.13 reported increased levels of glutamate in the
prefrontal cortex in postmortem brain samples from MDD and
bipolar disorder, suggesting a role of the glutamatergic system in
mood disorders. A noninvasive in vivo proton magnetic resonance
spectroscopy (1H-MRS) study revealed increased levels of gluta-
mate in the occipital cortex of patients with MDD,14 although
other 1H-MRS studies found decreased levels of Glx (glutamate
and glutamine) in the anterior cingulate cortex15 and dorsome-
dial/dorsal anterolateral prefrontal cortex16 in patients with MDD.
In contrast, there was no difference in glutamate levels in the
occipital cortex between MDD patients and controls.17 A recent
MRS study showed that young MDD (N =90) and bipolar disorder
(N= 75) groups (18–30 years) did not show different levels of
hippocampal glutamate compared with controls (N =40).18 A
recent meta-analysis showed a signiﬁcant reduction in Glx levels,
but not glutamate levels alone, in the brains of depressed patients
compared with controls across the studies included.19
Levine et al.20 reported higher cerebrospinal ﬂuid (CSF) levels of
glutamine in unmedicated patients with MDD. In contrast, a study
showed low glutamate levels in the CSF of refractory patients with
affective disorder.21 A recent study showed no signiﬁcant
differences between the control (N= 25) and the MDD groups
(N= 18) in baseline CSF levels of glutamate (P =0.761) and
glutamine (P=0.226).22 Thus, the results of studies on CSF levels
of glutamine and glutamate in MDD patients are inconsistent. At
present, there is no report that has evaluated the ratio of
glutamine to glutamate in CSF of MDD patients although this ratio
is an index of glutamine–glutamate cycle in glia–neuron
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communication.5,6,8,23,24 As the abnormalities in NMDA-R neuro-
transmission by altered glutamine–glutamate cycle in the brain
may be involved in the pathophysiology of MDD,5,6 it is of great
interest to examine CSF levels of amino acids related with NMDA-R
in elderly patients with MDD, and age- and gender-matched
healthy controls.
In the present study, we measured CSF levels of amino acids (for
example, glutamate, glutamine, glycine, D-serine and L-serine) in
elderly patients with MDD, and age- and gender-matched healthy
controls. All these amino acids can affect glutamatergic neuro-
transmission via the NMDA-R.13,25 Furthermore, we also measured
3-year follow-up CSF samples in these subjects.
MATERIALS AND METHODS
Participants
This study was approved by the institutional review boards of the Nathan
Kline Institute for Psychiatric Research and the New York University School
of Medicine. Participants were volunteers who responded to advertise-
ments in local newspapers and ﬂyers, or were recruited from the Memory
Education and Research Initiative Program.26 All participants provided
informed consent before examination, and received up to $450.00 in
compensation. A total of 133 participants completed the baseline
evaluation, and 51 of these took part in the optional lumbar puncture
procedure. Of these 51 participants, 3 were excluded because of evidence
in their magnetic resonance imaging scans of conﬂuent deep or
periventricular white matter hyperintensities, deﬁned as one or more
hyperintense lesions measuring at least 10 mm in any direction. One
individual was excluded because of a Mini-Mental State Examination
(MMSE) score below 28. Of the 47 remaining participants, 28 were
diagnosed with MDD by a board-certiﬁed psychiatrist, leaving 19
comparison subjects. The structural interview for DSM-IV disorders (SCID)
was administered by a psychiatrist to establish an MDD diagnosis. Of the
28 individuals with MDD, 21 (75%) had recurrent episodes. Table 1
summarizes the demographic and clinical characteristics of the study
participants at baseline.
Procedure
The study was conducted over four visits, usually 1 week apart. The ﬁrst
three visits were conducted at the Nathan Kline Institute for Psychiatric
Research and the Clinical and Translational Science Institute, New York
University Langone Medical Center. During the ﬁrst visit, for the purpose of
obtaining informed consent, study procedures were explained and
participants were informed of their rights. Participants’ medical and
psychiatric histories, including family history of AD, were also obtained,
and their vital signs were measured. Participants then underwent a
psychiatric evaluation, and their global cognitive status was assessed using
the MMSE. In addition, the Hamilton Depression Rating Scale (HAM-D) was
administered to rate the severity of current depressive symptoms. Subjects
who met the criteria for past MDD but were not currently depressed (that
is, HAM-D score below 16) were included as MDD subjects. Blood was
drawn for routine medical testing and APOE genotyping. During the
second visit, participants underwent a magnetic resonance imaging scan
of the head to quantify the magnitude of vascular brain pathology. During
the third visit, subjects underwent a comprehensive neuropsychological
assessment, including the Buschke Selective Reminding Test,27 the Trail-
Making Test parts A and B,28 and the category ﬂuency test.29
Finally, during the fourth visit, a lumbar puncture was performed by a
neuroradiologist under guided ﬂuoroscopy in a subset of participants.
Before the procedure, which was performed between 0900 and 1000 hours,
participants were asked to fast overnight. A total of 15 ml of clear CSF was
collected in three polypropylene tubes labeled ‘A’ (ﬁrst 5 ml), ‘B’ (second
5 ml) and ‘C’ (third 5 ml). The tubes were immediately placed on ice for a
maximum of 1 h until the samples were centrifuged at 4 °C (at 1500 r.p.m.)
for 10 min. Then, aliquots of 0.25 ml were placed into 1.00-ml poly-
propylene cryogenic vials and put into Nunc eight-cell storage boxes
(Nalge Nunc International, Rochester, NY, USA) at − 80 °C. All amyloid-β, tau
and amino-acid determinations were performed from tube ‘C’.
Among these participants, MDD patients (N= 19) and comparison
control subjects (N= 17) were followed for 3 years. Fifteen individuals with
MDD were receiving antidepressant treatment at the time of testing, but
no differences in amyloid-β42 levels were observed within the MDD group
as a function of antidepressant treatment.26 Clinical data, including
physical examination, routine laboratory tests, psychiatric evaluations,
HAM-D rating scale, cognitive functions and CSF samples, were collected at
3-year follow-up.
Measurement of amino acids
This study was also approved by the Research Ethics Committee of the
Graduate School of Medicine, Chiba University. Measurement of CSF levels
of amino acids was carried out using high-performance liquid chromato-
graphy (HPLC) system (Shimadzu Corporation, Kyoto, Japan) as previously
reported.23,25,30 Brieﬂy, 15 μl of H2O (HPLC grade), 20 μl of 0.1 M borate
buffer (pH 8.0) and 60 μl of 50 mM NBD-F in CH3CN (HPLC grade) were
added into 5 μl of CSF sample. The reaction mixture was then heated at
60 °C for 2 min, and immediately supplemented with 100 μl of H2O/CH3CN
(90/10) containing 0.1% triﬂuoroacetic acid to stop the reaction.
For determination of DL-serine, L-serine and D-serine, a 20-μl aliquot of
the resultant solution was injected into the HPLC system.25,30 A reversed-
phase ODS column (TSKgel ODS-80Ts (Tosoh Corporation, Tokyo, Japan) as
column 1) was used for the separation and quantiﬁcation of total (D- and L-)
serine, and the gradient elution of the mobile phase was maintained at a
constant ﬂow rate of 0.8 ml min− 1. Mobile phase 1a consisted of H2O/
CH3CN (90/10) containing 0.1% triﬂuoroacetic acid, and phases 1b and 1c,
of H2O/CH3CN (10/90) containing 0.1% triﬂuoroacetic acid and CH3CN,
respectively. The time program for gradient elution was as follows: 0–
25 min 1a:1b:1c= 92:8:0; 25–25.1 min linear gradient from 8% 1b to 100%
1b; 25.1–35 min 1a:1b:1c= 0:100:0; 35–35.1 min linear gradient from 8% 1b
to 100% 1c; 35.1–40 min 1a:1b:1c = 0:0:100; and 40.1–60 min 1a:1b:1c=
92:8:0. The chiral column (column 2) used for the separation and
quantiﬁcation of D- and L-serine with NBD-F comprised two Sumichiral
OA-2500 columns (Sumika Chemical Analysis Service, Osaka, Japan), which
were connected in tandem. The mobile phase was 15 mM citric acid in
MeOH. The ﬂow rate was isocratically pumped at 1.0 ml min − 1. The
column temperature of all columns was maintained at 35 °C. Fluorescence
detection was performed at 530 nm, with an excitation wavelength at
470 nm.
For determination of glycine, glutamine and glutamate, a reversed-
phase ODS column (TSKgel ODS-80Ts, Tosoh Corporation) was used.23,30
The gradient elution of the mobile phase was kept at a constant ﬂow rate
of 0.8 ml min− 1. The time program for gradient elution was programmed
as follows: 0–50.5 min 1a:1b:1c = 95:5:0; 50.5–55.5 min 1a:1b:1c = 0:100:0;
and 55.5–57 min 1a:1b:1c = 0:0:100. The column temperature of all
columns was maintained at 35°C. Fluorescence detection was performed
at 530 nm, with an excitation wavelength at 470 nm.
Statistical analysis
First, Student t- and χ2-tests were used to compare the MDD and
comparison groups with respect to dimensions not associated with
depression (that is, MMSE score, years of education, body mass index, age,
incidence of diabetes, gender, APOE status and reported family history of
AD; Table 1). Second, Student t-test was used to compare the two
diagnostic groups with respect to all remaining CSF variables. Third, 3-year
follow-up data were analyzed using a 2X2 repeated-measures analysis of
variance; the factors were time (baseline and follow-up) and MDD status
(MDD and controls). All tests were two-tailed, and statistical signiﬁcance
was established at an α of 0.05, unless differently noted. All analyses were
conducted using SPSS 22 (SPSS, Chicago, IL, USA).
RESULTS
As reported previously,26 the two groups at baseline did not differ
on any relevant clinical or demographic variable, with the
exception of the mean HAM-D score, which was signiﬁcantly
higher in the MDD group (Table 1). Of note, the proportion of
participants with a reported family history of AD was slightly
higher in the comparison group than in the MDD group. The CSF
levels of amyloid-β42 in the MDD group at baseline were
signiﬁcantly lower than those of the comparison group, whereas
differences in CSF levels of amyloid-β40, and total and phosphory-
lated tau protein at baseline did not reach statistical signiﬁcance
across conditions (Table 1).26
There were no signiﬁcant differences in levels of ﬁve amino
acids (glutamine, glutamate, glycine, L-serine and D-serine)
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between the MDD (N=28) and the comparison groups (N =19) at
baseline (Table 2). However, the ratio of glutamine to glutamate in
the MDD group was signiﬁcantly higher than in the comparison
group, whereas the ratio of glycine to L-serine and the ratio of D-
serine to L-serine did not differ (Table 2). Furthermore, there were
no correlations between CSF amino acids and typical AD
biomarkers (amyloid-β42, amyloid-β40, and total and phosphory-
lated tau protein) at baseline in all subjects (data not shown).
At the 3-year follow-up, an interaction between time and MDD
status was observed for the HAM-D scores. Post hoc comparisons
conﬁrmed that the severity of depression decreased over time in
participants with MDD (P=0.001), whereas no change was
detected in controls (P =0.366; Table 3 and Figure 1). When the
same repeated-measures analysis of variance was applied to CSF
levels of amino acids, no further interactions or main effects were
observed when setting α at 0.006 (Sidak correction; eight tests),
although a trend was observed for an interaction with the
glutamine/glutamate ratio (Table 3 and Figure 1). Post hoc
comparisons suggested that there was a decrease in this ratio in
MDD subjects (P= 0.008), but no appreciable change in controls
(P=0.571). Finally, we observed a marginally signiﬁcant negative
correlation (r =− 0.328, P=0.051) between the change scores
(baseline to follow-up) of the glutamine/glutamate ratio and of
Table 1. Demographic and clinical characteristics of cognitively intact individuals with MDD and age-matched comparison subjects at baseline
Characteristic Comparison group (N = 19) MDD group (N=28) Statistical analysis
t df P
Age (years) 68.1± 7.3 66.5± 5.4 0.835 45 0.41
Education (years)a 16.7± 2.7 16.5± 2.7 0.274 44 0.79
Body mass index 28.1± 4.7 28.8± 6.7 0.378 45 0.71
21-item HAM-D 1.2± 1.9 14.9± 8.8 8.02 45 o0.001
MMSE 29.5± 0.5 29.8± 0.6 1.56 45 0.13
Total recall rating 64.4± 12.3 64.9± 13.9 0.11 45 0.91
Delayed recall rating 8.5± 2.8 9.5± 2.5 1.258 45 0.22
Trail-Making Test score
Part A 37.2± 12.4 36.0± 14.1 0.303 45 0.76
Part B 80.3 ± 31.5 86.1± 23.2 0.737 45 0.47
Category ﬂuency test 41.7± 8.1 40.6± 8.2 0.45 45 0.66
N (%) N (%) χ2 df P
Diabetes 4 (21) 5 (18) 0.08 1 0.79
Female 12 (63) 10 (36) 2.41 1 0.12
Apolipoprotein ε level
ε4 5 (26) 11 (39) 0.369 1 0.54
ε2 6 (32) 7 (25) 0.03 1 0.87
Family history of Alzheimer's disease 6 (32) 3 (11) 3.3 1 0.07
pg ml− 1 pg ml− 1 t df P
Amyloid-β42 335.4± 182.7 224.7± 125.1 2.471 45 0.02
Amyloid-β40 6518.0± 2687.0 5146.0± 2369.0 1.845 45 0.07
Total tau proteinb 328.7± 151.7 273.0± 114.3 1.422 44 0.16
Phosphorylated tau protein 51.6± 20.9 48.9± 25.9 0.371 45 0.71
Abbreviations: df, degrees of freedom; 21-item HAM-D, 21-item Hamilton Depression Rating Scale; MDD, major depressive disorder; MMSE, Mini-Mental State
Examination. The data are mean± s.d. The data at baseline are from Pomara et al.26 aData for one control subject were not available. bData for one MDD
patient were not available.
Table 2. CSF levels of amino acids and ratio of amino acids in subjects at baseline
Characteristic Comparison group at baseline (N = 19) MDD group at baseline (N= 28) Analysis
t df P
Glutamine 568.17± 81.19 591.04± 87.78 0.903 45 0.371
Glutamate 0.647± 0.82 0.382± 0.11 1.407 18.5a 0.176
Glycine 12.99± 5.95 11.38± 2.67 1.103 23.0a 0.282
L-Serine 25.45± 5.58 22.36± 5.13 1.955 45 0.057
D-Serine 1.76± 0.38 1.75± 0.43 0.093 45 0.926
Glutamine/glutamate 1257.6± 458.4 1645.6± 434.7 2.938 45 0.005b
Glycine/L-serine 0.496± 0.14 0.526± 0.14 0.7 45 0.488
D-Serine/L-serine 0.072± 0.021 0.080± 0.019 1.326 45 0.192
Abbreviations: CSF, cerebrospinal ﬂuid; df, degrees of freedom; MDD, major depressive disorder. The data are mean± s.d. aEquality of variance assumption
not met. bDenotes signiﬁcant ﬁnding at α= 0.006 after Sidak’s adjustment (eight tests).
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HAM-D scores in all subjects, suggesting that as depression
severity decreased, so did the ratio.
DISCUSSION
In the present study, we found that older individuals with MDD
showed an increased CSF glutamine/glutamate ratio compared
with controls, although CSF levels of the individual amino acids
were not different. To our knowledge, this is the ﬁrst report in the
literature of an increase in the glutamine/glutamate ratio in elderly
MDD subjects, suggesting abnormalities in the glutamine–
glutamate cycle in the brains of elderly depressed individuals.
As the glutamine/glutamate ratio is an index for glutamine–
glutamate cycle in the glia–neuron communication,8,23 it is likely
that abnormalities in the glutamine–glutamate cycle in the brain
have a role in the pathophysiology of late-life depression.
We previously reported a reduction of amyloid-β42 in the same
MDD patients at baseline.26 Importantly, the glutamine/glutamate
ratio in elderly MDD patients was no longer signiﬁcantly different
from controls after a 3-year period; the loss of signiﬁcance
coincided with reduction in the severity of depressive symptoms,
suggesting that abnormalities in this ratio in depression may be
state- and not trait-dependent. However, we found no signiﬁcant
correlations between the ratio or levels of the individual amino
acids and AD biomarkers, or severity of depressive symptoms
either at the baseline or follow-up. These results are generally
consistent with previous ﬁndings of CSF studies that also reported
a lack of signiﬁcant correlations between these amino acids and
severity of depressive symptoms. Garakani et al.22 reported no
signiﬁcant differences between controls and MDD patients in
baseline CSF levels of glutamate (P =0.761) or glutamine
(P= 0.226). Furthermore, there was a signiﬁcant positive correla-
tion (r=0.677, P=0.016) between intensity of suicidal ideation and
CSF glutamate, and a signiﬁcant negative correlation (r =− 0.558,
P=0.038) between baseline HAM-D score and the glutamate/
glutamine ratio in adult patients (mean age of 40.4 years) with
MDD. It is thus very difﬁcult to reconcile the lack of signiﬁcant
correlations between the CSF ratio and severity of depressive
symptoms with evidence that the increased CSF glutamine/
glutamate ratio and other glutamatergic abnormalities associated
with MDD might be state-dependent. Taken together, these
ﬁndings highlight the limitations of static indices such as levels of
glutamate or glutamine either in CSF or brain to reﬂect dynamic
and brain region-speciﬁc alterations in the glutamatergic function.
Using in vivo 13C-MRS and [1-13C]glucose in a single voxel
spectroscopy study, Abdallah et al.31 found that measures of the
neuronal tricarboxylic acid cycle in the occipital cortex from
medication-free MDD patients was 26% lower compared with
controls, suggesting mitochondrial dysfunction in depression.
However, they reported no signiﬁcant alterations in the
Table 3. HAM-D score and CSF levels of amino acids and ratio in subjects at baseline and 3-year follow-up
Characteristic Baseline Baseline 3-year follow-up 3-year follow-up Analyses (P-values)
Comparison group
(N= 17)
MDD group (N=19) Comparison group
(N= 17)
MDD group (N=19) ME time ME MDD Interaction
21-item HAM-D 1.118± 1.900 17.105± 10.493 2.235± 6.006 8.737± 8.096 0.005 o0.001 o0.001
Glutamine 567.0± 83.2 587.1± 85.1 604.8± 80.7 594.5± 90.4 0.175 0.835 0.359
Glutamate 0.680± 0.86 0.399± 0.116 0.655± 0.788 0.652± 0.658 0.482 0.355 0.395
Glycine 13.30± 6.18 11.96± 2.79 13.2± 4.51 13.37± 5.20 0.456 0.668 0.388
L-Serine 25.8± 5.68 23.23± 5.69 25.0± 5.66 25.4± 7.79 0.564 0.537 0.207
D-Serine 1.76± 0.40 1.75± 0.45 1.80± 0.41 1.91± 0.49 0.09 0.717 0.315
Glutamine/
glutamate
1221.98± 472.7 1571.21± 440.2 1311.06± 463.9 1230.63± 455.9 0.192 0.271 0.029
Glycine/L-serine 0.501± .147 0.536± 0.153 0.546± 0.208 0.535± 0.128 0.467 0.787 0.454
D-Serine/L-serine 0.071± .021 0.078± 0.021 0.074± 0.018 0.079± 0.021 0.277 0.41 0.673
Abbreviations: CSF, cerebrospinal ﬂuid; 21 HAM-D, 21-item Hamilton Depression Rating Scale; MDD, major depressive disorder; ME MDD, main effect of MDD
status (depressed and controls); ME time, main effect of time (baseline and follow-up). The data are mean ± s.d. The analysis method used was 2 × 2 repeated-
measures analysis of variance.
Figure 1. Three-year follow-up of elderly MDD patients and control comparison. (a) The ratio of glutamine to glutamate in the cerebrospinal
ﬂuid (CSF) from major depressive disorder (MDD) patient group (N= 19) was signiﬁcantly decreased at 3-year follow-up. In contrast, the ratio
of glutamine to glutamate in the CSF from control comparison group (N= 17) was slightly increased at 3-year follow-up. (b) The Hamilton
Depression Rating Scale (HAM-D) score in the MDD patient group (N= 19) was signiﬁcantly decreased at 3-year follow-up. In contrast, HAM-D
score in the control comparison group (N= 17) was slightly increased at 3-year follow-up.
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glutamine–glutamate cycle and γ-aminobutyric acid (GABA)
synthesis, inconsistent with our CSF ﬁndings. Furthermore, this
study did not ﬁnd any correlations with severity of depression.31
One possibility is that the investigators focused only on the
occipital cortex, and they did not examine CSF or other brain
regions in which glutamatergic abnormalities have been found.
Glutamate is synthesized from glutamine by glutaminase, and
metabolized to glutamine by the mainly astrocyte-located GS. In
addition, glutamate is metabolized to GABA by glutamic acid
decarboxylase (GAD).8 Released glutamate is taken up by
surrounding astrocytes via the glutamate transporter, where it is
converted to glutamine, transported back to presynaptic neurons
and reconverted to glutamate. Thus, the glutamine–glutamate–
GABA cycle as part of glia–neuron communication has an
important role in excitatory and inhibitory neurotransmission.8
The expression of GS mRNA was reduced in the prefrontal cortex,
premotor cortex and amygdala from depressed suicide subjects,
but not in suicide completers without depression.32,33 Further-
more, GS protein was decreased in the anterior cingulate cortex
and orbitofrontal cortex from depressed patients.32,34,35 A recent
study using postmortem brain samples showed that the density of
GS-expressing astrocytes was signiﬁcantly reduced in some
cortical areas from MDD patients, suggesting a disturbance in
the glutamine–glutamate cycle in MDD.36 Moreover, the immu-
noreactivity of EAAT2, one of the glutamate transporters in
astrocytes, in the orbitofrontal cortex was signiﬁcantly lower in
MDD patients.35 In addition, increased immunoreactivity for
GAD65/67 was demonstrated in neurons from several cortical
regions, including orbitofrontal and dorsolateral prefrontal cortex,
in depressed patients.37 By contrast, the amount of GAD67 in the
dorsolateral prefrontal cortex of MDD patients was signiﬁcantly
reduced as compared with matched controls.38 These ﬁndings
suggest a dysregulation of the glutamate–GABA cycle in depres-
sion. Taken together, it is likely that abnormalities in the
glutamine–glutamate–GABA cycle in the brain have a role in the
pathophysiology of depression.
In this study, we found that the glutamine/glutamate ratio in
MDD patients was signiﬁcantly decreased after 3-year follow-up in
concert with improvement in depressive symptoms. Given the role
of glutamatergic neurotransmission in the mechanisms of
antidepressants,5,6 it is noteworthy that symptom improvement
caused by antidepressants may be mediated by effects on
glutamine–glutamate cycle in the brains from depressed patients.
In contrast, HAM-D score and the glutamine/glutamate ratio in
healthy subjects were slightly increased after 3-year follow-up,
although these increases were not statistically signiﬁcant.
CSF levels of glutamine in individuals with AD were reported to
be lower than in controls,39 whereas CSF levels of glutamate were
higher.40,41 Although the glutamine/glutamate ratio was not
measured in either study, and depression was not a focus of
either investigation, these results do not support a link between
the abnormalities in the glutamine–glutamate cycle in depression
with those in AD. Increased CSF levels of GS in individuals with AD
compared with controls also has been reported.42,43 In contrast, a
recent study using a quantitative ELISA system showed that CSF
levels of total GS in AD patients were not different from those
observed in healthy controls,44 suggesting that total CSF levels of
GS may not be a suitable biomarker for AD, or that further work
needs to be done with this biomarker to clarify whether GS
abnormalities exist in AD that are associated with the apparent
abnormalities in mood disorders.
The NMDA-R antagonist ketamine is known to produce a rapid
and sustained antidepressant effect in treatment-resistant patients
with MDD.11,12 A recent MRS study demonstrated that a single
infusion of ketamine (0.5 mg kg − 1) caused an increase of Glx and
GABA in the medial prefrontal cortex of MDD patients in ~ 26
min,45 indicating that ketamine has a rapid effect on the
glutamine–glutamate–GABA cycle in the prefrontal cortex in
depressed patients. In contrast, earlier studies showed that a
single infusion of ketamine (0.5 mg kg − 1) did not produce
changes in glutamate and glutamine concentrations in occipital
cortex in MDD patients,46 or in the anterior cingulate/medial
prefrontal cortex in healthy subjects,47 suggesting that changes in
occipital amino-acid levels are not correlated with ketamine’s
antidepressant action. Thus, it would be of great interest to
measure CSF amino acids in MDD patients at baseline and after a
single ketamine infusion.
Finally, there are some limitations to this study that should be
noted. The main limitation was small sample size, and similar,
future studies in geriatric depression would likely beneﬁt from
larger sample sizes. Another limitation was the inability to
measure CSF GABA in the subjects of this study. We could not
measure CSF levels of GABA because these were below the lower
limit of detection of our HPLC system. Given the key role of
glutamine–glutamate–GABA cycle in glia–neuron
communication,5,8 it is of great interest to measure CSF GABA
levels using a high-sensitive analytical system (for example, LC/
MS/MS).
In conclusion, we found that the CSF ratio of glutamine/
glutamate levels in elderly patients with MDD was signiﬁcantly
higher than that of age-matched healthy controls, and that the
increased ratio in patients was signiﬁcantly decreased after 3-year
follow-up by medication in conjunction with decreased depres-
sion symptoms over this time period. These ﬁndings suggest that
abnormalities in the glutamine–glutamate cycle in the glia–
neuron communication have a role in the pathophysiology of
elderly depression. Further studies measuring CSF levels of amino
acids (for example, glutamine, glutamate and GABA) using larger
cohorts, particularly cohorts of antidepressant-naive patients, will
be of great interest.
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